The Food and Drug Administration (FDA) has approved enlicitide, a new daily pill designed to significantly lower LDL, or "bad" cholesterol. This medication can reduce LDL levels by nearly 60 percent, matching the effectiveness of the strongest injectable treatments currently available, but administered orally. This development represents a significant step in the ongoing effort to combat heart disease, the leading cause of death in the United States for approximately a century.
Cardiovascular disease is a global health crisis, responsible for roughly 20 million deaths worldwide each year and about one in five deaths in the U.S. in 2025. Despite its prevalence, the age-adjusted death rate from cardiovascular disease in the U.S. has fallen by about three-quarters since 1950. Deaths specifically from heart attacks have decreased by 89 percent since 1970, a testament to advancements in understanding and treatment.
The key to much of this progress lies in managing low-density lipoprotein (LDL) cholesterol. For decades, high LDL levels were difficult to manage effectively through lifestyle changes alone. However, new treatments now offer the ability to lower LDL cholesterol more effectively, easily, and at earlier stages of life.
The scientific journey leading to treatments like enlicitide began over 20 years ago. In the early 2000s, geneticists Helen Hobbs and Jonathan Cohen at University of Texas Southwestern studied individuals with unusually low cholesterol levels. They identified a genetic mutation in the PCSK9 gene in some Black Americans, which led to more efficient LDL clearance from the blood. Carriers of a strong variant of this mutation had approximately 28 percent lower LDL levels and an 88 percent lower risk of heart disease. This discovery provided a crucial target for drug development, leading to the creation of PCSK9 inhibitors that mimic this natural genetic protection.
While statins have long been a cornerstone of cholesterol management, they are not suitable for everyone due to side effects like muscle aches or insufficient LDL reduction. Enlicitide offers an alternative for these individuals, providing potent cholesterol-lowering effects comparable to injections but in a convenient pill form without the statin-associated muscle pain.
Future Directions in Heart Disease Treatment
Beyond pills, gene editing is emerging as a potential long-term solution, particularly for addressing medication adherence issues. Many patients discontinue statin therapy within a year, and even potent daily pills are only effective if taken consistently. Verve Therapeutics, now part of Eli Lilly, is developing a gene-editing treatment that aims to permanently alter the PCSK9 gene in the liver with a single infusion. Early trials have shown a significant and sustained reduction in LDL levels following a single dose.
Cholesterol management is only one aspect of fighting heart disease. Other critical factors include reduced smoking rates, which have fallen from around 40 percent of U.S. adults in the 1960s to under 15 percent today. Advances in treating high blood pressure have also been substantial, with early detection and effective generic medications now widely available. Additionally, GLP-1 agonists, commonly used for weight management, have demonstrated a significant impact on cardiovascular health, with one trial showing a 20 percent reduction in cardiovascular events with semaglutide.
Despite these advancements, challenges remain. The long-term impact of newer drugs like enlicitide on reducing actual deaths from heart disease is still under study, though injectable PCSK9 inhibitors have shown a 20 percent reduction in heart attacks and strokes. Furthermore, the landscape of heart disease is shifting. While heart attack deaths have declined, deaths from other conditions like heart failure and hypertensive disease have increased. This shift is partly due to people living longer after surviving heart attacks, allowing other heart conditions to emerge. Simultaneously, rising obesity rates, affecting about 40 percent of U.S. adults, are contributing to increased rates of diabetes and high blood pressure.
Access to these life-saving treatments is another significant hurdle. Enlicitide is priced at approximately $300 per month, with uncertain insurance coverage. The future gene-editing therapies are expected to be even more costly, potentially limiting initial access to the most severely ill patients. Given that over 60 percent of U.S. adults are projected to develop some form of heart disease in their lifetime, widespread accessibility of effective treatments is crucial.
Enlicitide represents a tangible advancement, transforming a critical but often unmanageable health metric into a factor that can be controlled with a simple daily pill. This quiet progress in medicine continues to redefine the fight against one of the world's deadliest conditions.